Quick Answer
DiaMedica Therapeutics Inc. reported Net Income of -$32.77 million for fiscal year 2025.
DiaMedica Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$32.77M -34.0% |
-$24.44M -26.1% |
-$19.38M -41.7% |
-$13.68M -0.6% |
-$13.59M -10.6% |
-$12.29M -15.4% |
| Total Assets | $61.37M +32.4% |
$46.34M -14.4% |
$54.16M +57.5% |
$34.40M -24.5% |
$45.55M +62.1% |
$28.09M +210.3% |
| Cash and Equivalents | $15.65M +417.3% |
$3.02M -33.4% |
$4.54M -3.9% |
$4.73M +0.4% |
$4.71M -36.5% |
$7.41M +90.8% |
| Stockholders Equity | $56.11M +37.8% |
$40.72M -20.2% |
$51.06M +60.4% |
$31.83M -27.7% |
$44.02M +69.2% |
$26.01M +241.5% |
| R&D Expense | $24.61M +29.2% |
$19.06M +45.4% |
$13.11M +67.2% |
$7.84M -10.6% |
$8.77M +6.8% |
$8.21M +3.9% |
| Operating Income | -$34.40M -28.9% |
-$26.68M -25.5% |
-$21.27M -51.9% |
-$14.00M -2.6% |
-$13.65M -7.5% |
-$12.70M -9.5% |
| Shares Outstanding | 53.74M +25.5% |
42.82M +12.8% |
37.96M +43.5% |
26.44M +0.0% |
26.44M +41.1% |
18.75M +56.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$8.62M | -37.4% | -12.0% |
| Total Assets | September 30, 2025 | $57.05M | +8.6% | +81.3% |
| Cash and Equivalents | September 30, 2025 | $3.33M | -19.5% | -19.1% |
| Stockholders Equity | September 30, 2025 | $51.62M | +7.6% | +90.0% |
| R&D Expense | September 30, 2025 | $6.44M | +29.2% | +10.6% |
| Operating Income | September 30, 2025 | -$9.03M | -31.2% | -12.8% |
| Shares Outstanding | September 30, 2025 | 52.08M | +21.8% | +20.9% |
- DiaMedica Therapeutics Inc. reported Net Income of -$32.77 million for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed a decrease of -34.0% in Net Income compared to the prior fiscal year.
- DiaMedica Therapeutics Inc. reported Total Assets of $61.37 million for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed an increase of +32.4% in Total Assets compared to the prior fiscal year.
- DiaMedica Therapeutics Inc. reported Cash and Equivalents of $15.65 million for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed an increase of +417.3% in Cash and Equivalents compared to the prior fiscal year.
- DiaMedica Therapeutics Inc. reported Stockholders Equity of $56.11 million for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed an increase of +37.8% in Stockholders Equity compared to the prior fiscal year.
- DiaMedica Therapeutics Inc. reported R&D Expense of $24.61 million for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed an increase of +29.2% in R&D Expense compared to the prior fiscal year.
- DiaMedica Therapeutics Inc. reported Operating Income of -$34.40 million for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed a decrease of -28.9% in Operating Income compared to the prior fiscal year.
- DiaMedica Therapeutics Inc. reported Shares Outstanding of 53.74 million shares for fiscal year 2025.
- DiaMedica Therapeutics Inc. showed an increase of +25.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: